Analyst
Citigroup
Equibles does not estimate personal net worth.
Jeff Meacham is recorded as Analyst at Citigroup. Jeff Meacham has spoken on 8 earnings calls across 4 companies, most recently for Gilead Sciences, Inc. on October 29, 2026. Those appearances were for Gilead Sciences, Inc. (GILD), BioNTech SE (BNTX), Moderna, Inc. (MRNA) and Ptc Therapeutics, Inc. (PTCT). The companies whose calls Jeff Meacham spoke on are classified in the Healthcare sector.
“I get the IRA impact longer term to HIV, but maybe can you talk about the trends you're seeing in 3Q? I wasn't sure the reason why you guys are now recognizing”
“I just had a bigger picture one on capital deployment. You know, you guys have a substantial cash position, but you're also streamlining the pipeline, you know, with the cost savings initiative.”
“And then maybe another question I'm going to go to is to Bart. If the interim data were positive, could that open an avenue for accelerated regulatory filing?”
“So maybe thinking about Japan and Brazil and then other geographies you're thinking about, you know, could these trends also be similar or is your internal expectation that is just too early to tell?”
Citigroup
Analyst
Transcript header (unverified)
Drug Manufacturers - General · Healthcare
BNTX
Biotechnology · Healthcare
MRNA
Biotechnology · Healthcare
